Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis

References

• Silverman MN, Sternberg EM. Matching therapy to body rhythms: an endocrine approach to treating rheumatoid arthritis. J. Rheumatol.37, 1981–1982 (2010).
   PubMedGoogle Scholar
• Alten R, Doering G, Cutolo M et al. Hypothalamus–pituitary–adrenal axis function in patients with rheumatoid arthritis treated with night-time-release prednisone. J. Rheumatol.37, 2025–2031 (2010).
   PubMed Web of Science ®Google Scholar
• Alten R, Nolte M, Doering G, von Weder K. Circadian versus ultradian glucocorticoid regimen in the treatment of rheumatoid arthritis. Akt Rheumatol.34, 1–7 (2009).
   Google Scholar
• Arvidson NG, Gudbjörnsson B, Larsson A, Hällgren R. The timing of glucocorticoid administration in rheumatoid arthritis. Ann. Rheum. Dis.56, 27–31 (1997).
   PubMed Web of Science ®Google Scholar
• Straub RH. Concepts of evolutionary medicine and energy regulation contribute to the etiology of systemic chronic inflammatory diseases. Brain Behav Immun.25, 1–5 (2011).
   PubMed Web of Science ®Google Scholar
• Cutolo M, Seriolo B, Craviotto C, Pizzorni C, Sulli A. Circadian rhythms in RA. Ann. Rheum. Dis.62, 593–596 (2003).
   PubMed Web of Science ®Google Scholar
• Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum.56, 399–408 (2007).
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum.31, 315–324 (1988).
   PubMed Web of Science ®Google Scholar
• Khan NA, Yazici Y, Calvo-Alen J et al. Reevaluation of the role of duration of morning stiffness in the association of rheumatoid arthritis activity. J. Rheumatol.36, 2435–2442 (2009).
   PubMed Web of Science ®Google Scholar
• Yazici Y, Pincus T, Kautiainen H, Sokka T. Morning stiffness in patients with early rheumatoid arthritis is associated more strongly with functional disability than with joint swelling and erythrocyte sedimentation rate. J. Rheumatol.31, 1723–1726 (2004).
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ et al. Rheumatoid arthritis classification criteria. Arthritis Rheum.62, 2569–2581 (2010).
   PubMed Web of Science ®Google Scholar
• da Silva JAP, Phillips S, Buttgereit F. Impact of impaired morning function on the lives and well-being of patients with rheumatoid arthritis. Scand. J. Rheumatol.40(Suppl. 125), 6–11 (2011).
   Web of Science ®Google Scholar
• Westhoff G, Buttgereit F, Gromnica-Ihle E, Zink A. Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis. Rheumatology47, 980–984 (2008).
   PubMed Web of Science ®Google Scholar
• Franke LC, Ament AJ, van de Laar MA, Boonen A, Severens JL. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin. Exp. Rheumatol.27(4 Suppl. 55), S118–S123 (2009).
   PubMed Web of Science ®Google Scholar
• Ziegler S, Huscher D, Karberg K, Krause A, Wassenberg S, Zink A. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997–2007: results from the national database of the German collaborative arthritis centres. Ann. Rheum. Dis.69, 1803–1808 (2010).
   PubMed Web of Science ®Google Scholar
• Buttgereit F. How should impaired morning function in rheumatoid arthritis be treated? Scand. J. Rheumatol.40(Suppl. 125), 28–39 (2011).
   Web of Science ®Google Scholar
• Feldmann M, Maini RN. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J. Immunol.185, 791–794 (2010).
   PubMed Web of Science ®Google Scholar
• Cutolo M, Villagio B, Otsa K, Aakre O, Sulli A, Seriolo B. Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease’s symptoms. Autoimmunity Rev.4, 497–502 (2005).
   PubMed Web of Science ®Google Scholar
• Straub RH, Cutolo M, Buttgereit F, Pongratz G. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J. Intern. Med.267, 543–560 (2010).
   PubMed Web of Science ®Google Scholar
• Kirwan JR, Clarke L, Hunt LP, Perry MG, Straub RH, Jessop DS. Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis. Ann. NY Acad. Sci.1193, 127–133 (2010).
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Burmester GR, Straub RH, Seibel MJ, Zhou H. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum.63, 1–9 (2011).
   PubMed Web of Science ®Google Scholar
• Vogt M, Derendorf H, Krämer J et al. Biowaver monographs for immediate release solid oral dosage forms: prednisone. J. Pharmaceutical Sci.96, 1480–1489 (2007).
   PubMedGoogle Scholar
• Kirkham BW, Panayi GS. Diurnal periodicity of cortisol secretion, immune reactivity and disease activity in rheumatoid arthritis: implications for steroid treatment. Br. J. Rheumatol.28, 154–157 (1989).
   PubMedGoogle Scholar
• Hoes JN, Jacobs JWG, Boers M et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann. Rheum. Dis.66, 1560–1567 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobs JW, Bijlsma JW. Modified release prednisone in patients with rheumatoid arthritis. Ann. Rheum. Dis.69, 1257–1259 (2010).
   PubMedGoogle Scholar
• Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis.69, 964–975 (2010).
   PubMed Web of Science ®Google Scholar
• Alten R, Pohl C, Choy EH et al. Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA flare definition working group. J. Rheumatol.38, 1745–1750 (2011).
   PubMed Web of Science ®Google Scholar
• Contreras-Yáñez I, Ponce De León S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am. J. Med. Sci.340, 282–290 (2010).
   PubMed Web of Science ®Google Scholar
• Al-Habet SMH, Rogers HJ. Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets. Eur. J. Clin. Pharmacol.37, 423–426 (1989).
   PubMedGoogle Scholar
• Clarke LL, Jessop DS, Hunt LP, Straub RH, Perry MG, Kirwan JR. Alleviation of morning joint stiffness by low dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol. Int. J. Clin. Rheumatol.6, 241–249 (2011).
   Google Scholar
• Alten R. Clinical trials: insufficient data on glucocorticoid use in RA trials. Nat. Rev. Rheumatol.7, 318–319 (2011).
   PubMedGoogle Scholar
• Bijlsma JW, Hoes JN, van Everdingen AA, Verstappen SM, Jacobs JW. Are glucocorticoids DMARDs? Ann. N.Y. Acad. Sci.1069, 268–274 (2006).
   PubMed Web of Science ®Google Scholar
• Kirwan J, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst. Rev.4, CD006356 (2007).
   Google Scholar
• da Silva JA, Jacobs JW, Kirwan JR et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann. Rheum. Dis.65, 285–293 (2006).
   PubMed Web of Science ®Google Scholar
• Derendorf H, Ruebsamen K, Schaeffler A, Kirwan JR. Pharmacokinetics of modified-release prednisone tablets are essentially unchanged from conventional immediate release prednisone tablets except for a programmed delay of 4–6 hours. Ann. Rheum. Dis.70(Suppl. 3), 604 (2011).
   Google Scholar
• Kirwan JR. Targeting the time of day for glucocorticoid delivery in rheumatoid arthritis. Int. J. Clin. Rheumatol.6(3), 273–279 (2011).
   Google Scholar
• Buttgereit F, Doering G, Schaeffler A et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet371, 205–214 (2008).
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Doering G, Schaeffler A et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann. Rheum. Dis.69, 1275–1280 (2010).
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Mehta DP, Kirwan JR et al. Low-dose glucocorticoid chronotherapy of rheumatoid arthritis: 12 week efficacy data of 5 mg modified-release prednisone. Ann. Rheum. Dis.69(Suppl. 3), 220 (2010).
   Google Scholar
• Buttgereit F, Mehta DP, Kirwan JR et al. Safety data for low-dose glucocorticoid chronotherapy of rheumatoid arthritis with 5 mg modified-release prednisone in a randomized, double-blind placebo-controlled trial. Ann. Rheum. Dis.69(Suppl. 3), 219 (2010).
   Google Scholar
• Buttgereit F, Szechinski J, Doering G et al. Integrated summary of safety for modified-release prednisone compared to immediate release prednisone: results from the “Circadian administration of prednisone in rheumatoid arthritis” (CAPRA) studies. Ann. Rheum. Dis.70(Suppl. 3), 88 (2011).
   Google Scholar
• Bijlsma JW, Jacobs JW. Glucocorticoid chronotherapy in rheumatoid arthritis. Lancet371(183), 184 (2008).
   PubMedGoogle Scholar
• Hewlett S, Chalder T, Choy E et al. Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatology50, 1004–1006 (2011).
   PubMed Web of Science ®Google Scholar
• Westhoff G, Buttgereit F, Zink A. Fatigue and morning stiffness ar correlated in early arthritis and both are substantially improved by glucocorticoids. Ann. Rheum. Dis.70(Suppl. 3), 289 (2011).
   PubMedGoogle Scholar